Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal clinical trial assessing new three-monthly formulation of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg

Next Previous
Trial Profile

A pivotal clinical trial assessing new three-monthly formulation of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Pharmacokinetics; Registrational

Most Recent Events

  • 25 Mar 2025 According to ROVI media release, e company plans to commence the phase III clinical development of Letrozole SIE, two products based on ISM technology that will expand the portfolio of products developed internally, in the fourth quarter of 2025.
  • 08 May 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top